Catheter Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

Global Catheters Market Outlook

Global Catheters Market size is projected to reach around US$ 40.76 Billion by 2030, according to Renub Research. Catheterization is a scientific method concerning inserting a tube into the bladder to allow urine to flow freely. There are different kinds of catheters, which includes cardiovascular, neurovascular, urological, and uniqueness catheters. They are usually used for short intervals, which includes several weeks or months, when continuous bladder drainage is necessary. In a few cases, they will be required for long term use. Urinary catheters are used whilst individuals have issue passing urine naturally, and that they can also be used to empty the bladder before or after surgery. These devices, crafted from materials like plastic, rubber, or silicone in diverse sizes and designs. They serve vital purposes such as draining urine, handing over fluids or medicinal drugs, measuring blood pressure, and performing complicated interventions like angioplasty. They have transformed patient care by enabling minimally invasive techniques, decreasing the reliance on conventional surgical treatment, cutting recovery times, and improving patient comfort while upholding stringent standards of protection and efficacy across diverse medical disciplines.

Companies Recent Initiatives & Development

Abbott Laboratories

In February 2023, Abbott announced significant advancements in its global electrophysiology product line. The TactiFlex™ Ablation Catheter, with Sensor Enabled™ technology, became the only catheter worldwide to combine a flexible tip with contact force sensing. It received CE Mark approval for treating abnormal heart rhythms like atrial fibrillation (AFib). Furthermore, Abbott's FlexAbility™ Ablation Catheter, also with Sensor Enabled™ features, obtained expanded FDA approval for treating complex heart conditions.

In August 2021, Abbott unveiled key results from the Amulet™ LAA Occluder IDE trial, directly comparing Abbott's Amplatzer™ Amulet Left Atrial Appendage (LAA) Occluder with Boston Scientific's Watchman device for treating high-risk atrial fibrillation (AFib) patients. The trial confirmed the Amulet device's superiority in LAA closure while demonstrating its noninferiority in safety and effectiveness compared to the Watchman device.

Becton Dickinson and Company

In May 2023, BD introduced a convenient prefilled flush syringe for customers. This innovative BD PosiFlushSafeScrub syringe is designed to enhance patient care by expediting the flushing and disinfection of IV catheters during clinical procedures. Ensuring the cleanliness and disinfection of catheters is crucial in preventing CRBSIs.

In November 2023, Becton, Dickinson, and Company introduced an advanced ultrasound system to enhance clinician efficiency in placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines, and other vascular access devices.

In the Journal of the Association for Vascular Access, Jan 2021, Becton, Dickinson, and Company announced the publication of the first-ever peer-reviewed study to evaluate outcomes from using midline catheters for blood collection.

Boston Scientific Corporation

In December 2022, through strategic investment, Boston Scientific announced plans to acquire a controlling stake in Acotec Scientific Holdings Limited, a prominent Chinese medical technology company. Acotec is recognized in China for its thrombus aspiration catheters, radiofrequency ablation technologies, and drug-coated balloons (DCBs).

In January 2024, Boston Scientific Corporation disclosed FDA approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System, offering a novel alternative to thermal ablation for treating drug-resistant, recurring, symptomatic, intermittent atrial fibrillation (AF).

In March 2024, Boston Scientific Corporation revealed FDA approval for the AGENT™ Drug-Coated Balloon (DCB), designated for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease, addressing vessel narrowing caused by plaque or scar tissue.

Teleflex Incorporated

In February 2023, Teleflex Incorporated announced FDA clearance for its Triumph Catheter, boasting clear visualization and precise wire advancement. Additionally, the GuideLiner Coast Catheter had its inaugural clinical application at UW Medicine Heart Institute in Seattle, Washington.

In November 2023, Teleflex Incorporated unveiled the initiation of a clinical registry to assess outcomes of on-label use of the MANTA™ Vascular Closure Device (VCD) in transcatheter aortic valve replacement (TAVR) procedures, focusing on patient selection and vascular access.

In May 2023, Teleflex Incorporated introduced two innovative devices to improve PICC insertion procedures and minimize complications. The Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet collaborate to offer Vascular Access Specialists enhanced efficiency and predictability in PICC placement.

In May 2023, Teleflex Incorporated unveiled two innovative devices to improve PICC insertion and reduce complications. The Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet collaborate to provide Vascular Access Specialists with enhanced efficiency and predictability during PICC placement.

In February 2023, Teleflex Incorporated achieved significant milestones by releasing two new catheters: obtaining FDA 510(k) clearance for the Triumph™ Catheter and initiating the first clinical application of the GuideLiner® Coast™ Catheter.

Medtronic Plc.

In February 2022, Medtronic announced FDA approval for its FreezorXtra Cardiac Cryoablation and Freezor and Focal Catheters to treat juvenile Atrioventricular Nodal Reentrant Tachycardia (AVNRT). These single-use, flexible devices freeze cardiac tissue to block unwanted heart electrical signals.

In December 2023, Medtronic plc disclosed FDA approval for the PulseSelect Pulsed Field Ablation (PFA) System to treat paroxysmal and persistent atrial fibrillation (AF). This marks the first FDA-approved PFA technology, following its CE Mark in Europe in November.

In March 2023, Medtronic introduced the CE Mark-approved Affera™ Mapping and Ablation System, integrating Sphere-9™ Catheter and Affera™ Prism-1 Mapping Software. This system advances electrophysiology with PFA, RF, and HD mapping, providing real-time feedback. AFib, affecting 60 million worldwide, poses significant complications, including heart failure, stroke, and increased mortality, with an estimated five million new cases annually by 2030.

Johnson & Johnson

On November 30, 2023, Johnson & Johnson MedTech completed its acquisition of Laminar, Inc., a company specializing in LAA elimination for non-valvular AFib patients. The acquisition, valued at $400 million upfront with potential milestone payments, integrates Laminar into Biosense Webster, Inc., enhancing its position in cardiac arrhythmia treatment.

In February 2024, Biosense Webster, Inc., a Johnson & Johnson MedTech division and a leading figure in cardiac arrhythmia treatment, announced European CE mark approval for the VARIPULSE™ Platform. Integrating the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 System, this platform offers pulsed field ablation (PFA) for treating recurrent paroxysmal atrial fibrillation (AF). It's the sole CARTO™ -integrated PFA system, ensuring an intuitive workflow with real-time visualization and feedback.

In February 2024, Biosense Webster, Inc., a leader in cardiac arrhythmia treatment under Johnson & Johnson MedTech, presented findings from a company-funded study at the 29th Annual International AF Symposium. The study, "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," showed that reducing radiation exposure during catheter ablation for paroxysmal AFib maintains safety, efficacy, and long-term patient outcomes akin to traditional procedures.

Edwards Lifesciences Corporation

In February 2024, Edwards Lifesciences Corporation revealed that its EVOQUE tricuspid valve replacement system is the first transcatheter therapy approved by the FDA for treating tricuspid regurgitation (TR). It aims to enhance the health status of patients with symptomatic severe TR despite optimal medical therapy (OMT), which is suitable for cases where a heart team recommends tricuspid valve replacement.

In May 2023, Edwards Lifesciences presented data from the COMMENCE aortic trial at the 103rd annual American Association for Thoracic Surgery meeting. The findings revealed minimal structural valve deterioration rates in bioprosthetic aortic valves using RESILIA tissue, representing the most extended clinical follow-up, averaging 7.7 years.

Stryker Corporation

In August 2023, Stryker introduced the pioneering fully autonomous surgical guidance system for cranial and spinal surgery, incorporating the proprietary FP8000 camera. It navigates four times faster than Medtronic's StealthStation and 16 times faster than Globus Medical's ExcelsiusGPS. Leveraging imaging data from Stryker's AiroTruCT, surgeons can now plan intricate two- and three-dimensional procedures, including precise screw and catheter placement, with real-time alignment adjustments based on patient orientation. After successful testing in one operating room, the device is already operational in five university hospitals.

On December2022, Stryker launched its Neurovascular (NV) lab, the Keystone Suite, at the SGTC, International Park, Gurgaon, India. This advanced facility fosters collaboration and accelerates stroke-related innovation in Asia Pacific, addressing the region's critical healthcare needs with cutting-edge technology and dedicated physician interaction spaces.

Global Catheters Market size is expected to grow at a CAGR of 8.23% between 2023 and 2030

The growing prevalence of chronic sicknesses, spurred by the older populace, has generated a greater call for clinical interventions. Catheters have emerged as adaptable tools to manage these situations, with a developing focus on their advantages. Both patients and healthcare experts want minimally invasive catheter strategies because of their capacity to minimize complications, expedite healing, and decrease hospitalization periods. In cardiology, mainly through methods like angioplasty, stent placement, and transcatheter aortic valve alternative, catheters have shifted from specialized therapies to customary practices, underscoring their persevered significance. Together with evolving demographics and technological progress, this solidifies catheters as imperative in present-day healthcare, shaping numerous clinical domains and fueling the dynamic growth of the global catheter market size.

Besides, in the global catheter market size, key catheter advancements encompass advanced substances and coatings, such as antimicrobial layers, improving safety. Integration of robotics, sensors, and imaging technology similarly refines catheter performance, offering precision and real-time feedback. Novel catheter designs, together with steerable and atraumatic models, prioritize patient consolation and limit complications. These improvements promote safer, more powerful, and minimally invasive strategies, propelling extended catheter demand. Notably, Boston Scientific's novel device for atrial fibrillation treatment employs a steerable catheter and cryoablation balloon, marking sizeable development in addressing this common heart arrhythmia. Hence, the Global Catheter Market was worth US$ 23.43 Billion in 2023.

Transcatheter Aortic Valve Replacement (TAVR) has dominated the global catheter market

By Type, the global catheter market has been distinguished into TAVR, TMVR, and TPVR. Transcatheter Aortic Valve Replacement (TAVR) has captured the biggest percentage of the global catheter market size due to its progressive method of treating aortic valve diseases. TAVR offers a minimally invasive alternative to standard open-coronary heart surgical procedures, making it appropriate for a broader patient demographic. Its ability to increase life expectancy and enhance quality of life, specifically amongst aged and high-risk patients, has pushed its speedy adoption. Moreover, improvements in technology and medical expertise have increased safety and efficacy. TAVR's less invasive nature reduces restoration instances and hospital stays, making it a cost-effective and patient-friendly preference, solidifying its dominant position within the catheter market.

Global catheter market is seeing an increase in the use of biological tissue

By material, the global catheter market is divided into Mechanical tissues and biological tissue. Biological tissue is gaining prominence in the worldwide catheter market size due to its first-rate biocompatibility and ability to lower complications. As sufferers demand more secure and powerful medical techniques, the mixing of organic materials in catheters addresses this need. Bio-engineered tissues, along with the ones derived from animal or human resources, closely mimic the body's properties, lowering the hazard of adverse reactions or infections. These revolutionary catheters hold promise for packages like cardiovascular and urinary interventions, where minimizing irritation and improving recovery are paramount. The developing emphasis on patient effects, coupled with advancing biotechnology, guarantees that organic tissue continues to thrive within the catheter market.

Hospitals maintain a dominant share in the global catheter market

By end-user, the global catheter market is fragmented into Hospitals, Ambulatory surgical centers, and others. Hospitals, in most cases, dominate the global catheter market size, and this is attributed to their capacity to harness economies of scale as a way to secure stable pricing agreements with catheter producers. This cost-effective method allows hospitals to keep a sizable catheter supply while upholding top-tier patient care requirements. As a result, their strategic procurement strategies and infrastructure assist them as the key catalyst for the significant adoption of catheters, in addition to solidifying their outstanding popularity in the worldwide catheter market.

In the global catheter market, the transaortic approach is expected to grow at the fastest rate

By product, the global catheter market is segmented into the Transfemoral approach, Transapical approach, Transaortic approach, and others. The transaortic technique is poised for the quickest growth in the global catheter market size due to its flexible application and minimally invasive nature. It gives an instantaneous path to the coronary heart and is increasingly popular in transcatheter aortic valve replacement (TAVR) and other cardiac procedures. This method minimizes trauma and reduces healing times, making it attractive to both patients and physicians. With ongoing improvements and expanding indicators for the transaortic approach, it's expected to witness speedy adoption, driving its extended growth in the catheter market.

Aortic stenosis is expected to dominate the global catheter market

By application, the global catheter market is broken up into Aortic Stenosis, Aortic Regurgitation, and Others. Aortic stenosis will lead in the worldwide catheter market size because of its high prevalence and the vital need for an effective remedy. This condition, characterized by a narrowed aortic valve, often necessitates catheter-based interventions like transcatheter aortic valve replacement (TAVR). As the elderly population grows, so does the prevalence of aortic stenosis, fueling demand for these strategies. Advancements in catheter technology and increasing patient recognition solidify its prominence, making aortic stenosis the driving force in the worldwide catheter market size.

United States commands the largest share of the global catheter market

By nations, the worldwide catheter marketplace consists of the USA, Canada, Mexico, Brazil, Argentina, Germany, Spain, United Kingdom, Italy, France, Indonesia, Malaysia, India, Thailand, Japan, China, South Korea, Australia, South Africa, Saudi Arabia, UAE, Turkey, and New Zealand. The United States leads the global catheter market. Its well-established and advanced healthcare system, blended with a sizeable and aging population, creates a constant and large demand for various styles of catheters. The U.S. is likewise a hub for scientific innovation, with giant research and development investments necessary to create modern catheter technology.Also, the superiority of chronic sicknesses, which often require catheter-based interventions, contributes to market growth. Stricter regulatory requirements and quality assurance mechanisms enhance belief in catheter usage, collectively positioning the United States at the forefront of the global catheter market.

Competitive Landscape

Abbott Laboratories, Becton Dickinson and Company, Boston Scientific Corporation, Teleflex Incorporated, Medtronic Plc., Johnson & Johnson, Edwards Lifesciences Corporation, and Stryker Corporation are the major competitors in the global catheters market.

Renub Research report titled "Global Catheter Market Forecast By Type (TAVR, TMVR, and TPVR), material (Mechanical tissue and biological tissue), end-user (Hospitals, Ambulatory surgical centers, and others), products (Transfemoral approach, Transapical approach, Transaortic approach, and others), application (Aortic Stenosis, Aortic Regurgitation, and Others), Countries (USA, Canada, Mexico, Brazil, Argentina, Germany, Spain, United Kingdom, Italy, France, Indonesia, Malaysia, India, Thailand, Japan, China, South Korea, Australia, South Africa, Saudi Arabia, UAE, Turkey, and New Zealand), Companies (Abbott Laboratories, Becton Dickinson and Company, Boston Scientific Corporation, Teleflex Incorporated, Medtronic Plc., Johnson & Johnson, Edwards Lifesciences Corporation, and Stryker Corporation)" provides a detailed and comprehensive insight of the Global Catheter Industry.

Type – Market breakup from 3 viewpoints:

1.    TAVR
2.    TMVR
3.    TPVR

Material – Market breakup from 2 viewpoints:

1.    Mechanical tissue
2.    Biological tissue

End-User – Market breakup from 3 viewpoints:

1.    Hospitals
2.    Ambulatory surgical centers
3.    Others

Product – Market breakup from 4 viewpoints:

1.    Transfemoral approach
2.    Transapical approach
3.    Transaortic approach
4.    Others

Application – Market breakup from 3 viewpoints:

1.    Aortic Stenosis
2.    Aortic Regurgitation
3.    Others

Region – Market breakup from 25 Country viewpoints:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherland
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All companies have been covered from 3 viewpoints:

•    Overview
•    Recent Development
•    Revenue

Company Analysis:

1.    Abbott Laboratories
2.    Becton Dickinson and Company
3.    Boston Scientific Corporation
4.    Teleflex Incorporated
5.    Medtronic Plc.
6.    Johnson & Johnson
7.    Edwards Lifesciences Corporation
8.    Stryker Corporation

Report Details: